Delcath Systems, Inc. (DCTH)
Delivers high-dose chemotherapy directly to liver tumors while minimizing side effects.
$11.55-0.03%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+9.1%
The outlook
DCTH is trading near the middle of its 52-week range with mixed momentum against moving averages. Analyst coverage shows a notably bullish lean, with the average price target sitting roughly 87% above the current price, though the extremely high trailing P/E suggests limited current profitability.
What’s behind the score
Price trendMixed vs its moving averages
52-week range61% of the way from its 52-week low to high
Price targetAvg target +87% vs current price
Analyst price target
~12-month · 5 analysts$21.55average target+86.6% vs now
Now $11.55
Low $17.00High $29.76
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$398.7M
52-wk high
$13.74
52-wk low
$8.12
50-day avg
$11.96
200-day avg
$10.45
Trailing P/E
1155.0